Breaking News

ACM Global Appoints Clinical Ops VP

April 9, 2013

Jackle to oversee U.S.-based clinical trials

Timo Jackle has been appointed to the executive management team as vice president of clinical trials operations at ACM Global Central Lab. Mr. Jackle will be responsible for overseeing project management, data management, study support, specimen management, and logistics activities for all of ACM’s U.S.-based clinical trials, as well as developing and implementing its strategy for operations globally.
 
Mr. Jackle joins the company from Bausch & Lomb (B&L), where he most recently served as executive director of global clinical trials operations, responsible for overseeing multi-national pharmaceutical and medical device clinical trials. Prior to that, he was based in Germany, where he served as director of global refractive R&D and R&D site leader for B&L’s refractive surgery subsidiary. 
 
“Timo is a highly collaborative leader with extensive experience in clinical trials research, quality assurance, global operations, and business process improvement,” said Angela J. Panzarella, president of ACM Global Central Lab. “His strong focus on customer service and lengthy track record in improving business processes will no doubt be an asset to our clients.”

Related Packaging:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials